Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + gemcitabine + oxaliplatin + leucovorin + 5-fluorouracil + serplulimab + bevacizumab-Zhejiang Cancer Hospital-pancreatic ductal adenocarcinoma
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy regimen is being evaluated for the first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC). The regimen employs a sequential chemotherapy strategy, beginning with nab-paclitaxel and gemcitabine (AG) followed by modified FOLFOX (mFOLFOX, comprising oxaliplatin, leucovorin, and 5-fluorouracil). This cytotoxic backbone is integrated with serplulimab, a monoclonal antibody targeting the Programmed cell death protein 1 (PD-1) receptor, and bevacizumab (specifically the biosimilar HLX04), a monoclonal antibody targeting Vascular endothelial growth factor (VEGF). By combining sequential chemotherapy with immune checkpoint inhibition and anti-angiogenic therapy, the regimen aims to enhance therapeutic efficacy in the typically immunosuppressive and poorly vascularized microenvironment of pancreatic cancer. It is currently under investigation in Phase II and Phase III clinical trials led by Zhejiang Cancer Hospital.
- Other names
- nab-paclitaxel + gemcitabine + oxaliplatin + leucovorin + 5-fluorouracil + serplulimab + bevacizumabAG-mFOLFOX + Serplulimab + Bevacizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNAVEGFA (Vascular endothelial growth factor A)RNR (Ribonucleotide reductase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nab-paclitaxel + gemcitabine + oxaliplatin + leucovorin + 5-fluorouracil + serplulimab + bevacizumab-Zhejiang Cancer Hospital-pancreatic ductal adenocarcinoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + gemcitabine + oxaliplatin + leucovorin + 5-fluorouracil + serplulimab + bevacizumab-Zhejiang Cancer Hospital-pancreatic ductal adenocarcinoma.